Thermo Fisher (0R0H) Share Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0R0H Analyst Ratings

Strong Buy

14 Buy

3 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Thermo

Fisher

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0R0H Stock 12 Month Forecast

Average Price Target

$635.50

▲(4.73% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Thermo Fisher in the last 3 months. The average price target is $635.50 with a high forecast of $748.00 and a low forecast of $520.00. The average price target represents a 4.73% change from the last price of $606.81.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"469":"$469","539":"$539","609":"$609","679":"$679","749":"$749"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":748,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$748.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":635.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$635.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":520,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$520.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[469,539,609,679,749],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,601.61,612.8707692307693,624.1315384615385,635.3923076923077,646.6530769230769,657.9138461538462,669.1746153846154,680.4353846153846,691.6961538461538,702.9569230769231,714.2176923076923,725.4784615384615,736.7392307692307,{"y":748,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,601.61,604.2169230769231,606.8238461538461,609.4307692307692,612.0376923076923,614.6446153846153,617.2515384615384,619.8584615384616,622.4653846153847,625.0723076923077,627.6792307692308,630.2861538461539,632.8930769230769,{"y":635.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,601.61,595.3323076923077,589.0546153846154,582.7769230769231,576.4992307692307,570.2215384615384,563.9438461538462,557.6661538461539,551.3884615384616,545.1107692307693,538.8330769230769,532.5553846153846,526.2776923076923,{"y":520,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":491.691,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":521.593,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":567.381,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":583.785,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":581.667,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":581.468,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":508.71,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":496.226,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":470.292,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":493.908,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":513.751,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":573.91,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":601.61,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$748.00

Average Price Target$635.50

Lowest Price Target$520.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Luo CFA

CLSA

$748

Buy

23.27%

Upside

Initiated

09/03/26

Thermo Fisher initiated with an Outperform at CLSAThermo Fisher initiated with an Outperform at CLSA

Daniel Arias

Stifel Nicolaus

$600→$650

Buy

7.12%

Upside

Assigned

08/05/26

Thermo Fisher price target raised to $650 from $600 at StifelThermo Fisher price target raised to $650 from $600 at Stifel

Casey Woodring

J.P. Morgan

$690

Buy

13.71%

Upside

Reiterated

07/28/26

Analysts Are Bullish on These Healthcare Stocks: Centene (CNC), Ansell (ANSLF)

Jill Wu

CMB International Securities

$620→$660

Buy

8.77%

Upside

Reiterated

07/27/26

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR) and Thermo Fisher (NYSE: TMO)

David Westenberg

Piper Sandler

$510→$600

Hold

-1.12%

Downside

Reiterated

07/27/26

Thermo Fisher price target raised to $600 from $510 at Piper SandlerThermo Fisher price target raised to $600 from $510 at Piper Sandler

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

$570→$650

Buy

7.12%

Upside

Assigned

07/24/26

Thermo Fisher (TMO) Gets a Buy from Goldman Sachs

Matt Larew

William Blair

―

Buy

―

Reiterated

07/24/26

Thermo Fisher Rated Buy on Broad-Based Recovery, Conservative Guidance, and Attractive Valuation Versus Peers

Luke Sergott

Barclays

$625→$650

Buy

7.12%

Upside

Reiterated

07/24/26

Barclays Keeps Their Buy Rating on Thermo Fisher (TMO)

Kallum Titchmarsh

Morgan Stanley

$620→$650

Buy

7.12%

Upside

Reiterated

07/24/26

Analyst Raises Thermo Fisher Price Target to $650 on Improved Outlook and Portfolio Optimization

Daniel Brennan

TD Cowen

$625→$675

Buy

11.24%

Upside

Reiterated

07/23/26

Daniel Brennan Boosts Thermo Fisher Price Target to $675 on Strengthening Recovery and Improving Earnings Power

Brandon Couillard

Wells Fargo

$615

Buy

1.35%

Upside

Assigned

07/23/26

Analysts Offer Insights on Healthcare Companies: Integer Holdings (NYSE: ITGR), Thermo Fisher (NYSE: TMO) and AbbVie (NYSE: ABBV)

Dan Leonard

RBC Capital

$490→$580

Hold

-4.42%

Downside

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: Molina Healthcare (NYSE: MOH), Johnson & Johnson (NYSE: JNJ) and Thermo Fisher (NYSE: TMO)

Tycho Peterson

Jefferies

$650→$630

Buy

3.82%

Upside

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (NYSE: WST) and Thermo Fisher (NYSE: TMO)

Michael Ryskin

Bank of America Securities

$630→$650

Buy

7.12%

Upside

Reiterated

07/23/26

Thermo Fisher price target raised to $650 from $630 at BofAThermo Fisher price target raised to $650 from $630 at BofA

Eve Burstein

Bernstein

$520

Hold

-14.31%

Downside

Reiterated

07/22/26

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO) and Pfizer (NYSE: PFE)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Luo CFA

CLSA

$748

Buy

23.27%

Upside

Initiated

09/03/26

Thermo Fisher initiated with an Outperform at CLSAThermo Fisher initiated with an Outperform at CLSA

Daniel Arias

Stifel Nicolaus

$600→$650

Buy

7.12%

Upside

Assigned

08/05/26

Thermo Fisher price target raised to $650 from $600 at StifelThermo Fisher price target raised to $650 from $600 at Stifel

Casey Woodring

J.P. Morgan

$690

Buy

13.71%

Upside

Reiterated

07/28/26

Analysts Are Bullish on These Healthcare Stocks: Centene (CNC), Ansell (ANSLF)

Jill Wu

CMB International Securities

$620→$660

Buy

8.77%

Upside

Reiterated

07/27/26

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR) and Thermo Fisher (NYSE: TMO)

David Westenberg

Piper Sandler

$510→$600

Hold

-1.12%

Downside

Reiterated

07/27/26

Thermo Fisher price target raised to $600 from $510 at Piper SandlerThermo Fisher price target raised to $600 from $510 at Piper Sandler

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

$570→$650

Buy

7.12%

Upside

Assigned

07/24/26

Thermo Fisher (TMO) Gets a Buy from Goldman Sachs

Matt Larew

William Blair

―

Buy

―

Reiterated

07/24/26

Thermo Fisher Rated Buy on Broad-Based Recovery, Conservative Guidance, and Attractive Valuation Versus Peers

Luke Sergott

Barclays

$625→$650

Buy

7.12%

Upside

Reiterated

07/24/26

Barclays Keeps Their Buy Rating on Thermo Fisher (TMO)

Kallum Titchmarsh

Morgan Stanley

$620→$650

Buy

7.12%

Upside

Reiterated

07/24/26

Analyst Raises Thermo Fisher Price Target to $650 on Improved Outlook and Portfolio Optimization

Daniel Brennan

TD Cowen

$625→$675

Buy

11.24%

Upside

Reiterated

07/23/26

Daniel Brennan Boosts Thermo Fisher Price Target to $675 on Strengthening Recovery and Improving Earnings Power

Brandon Couillard

Wells Fargo

$615

Buy

1.35%

Upside

Assigned

07/23/26

Analysts Offer Insights on Healthcare Companies: Integer Holdings (NYSE: ITGR), Thermo Fisher (NYSE: TMO) and AbbVie (NYSE: ABBV)

Dan Leonard

RBC Capital

$490→$580

Hold

-4.42%

Downside

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: Molina Healthcare (NYSE: MOH), Johnson & Johnson (NYSE: JNJ) and Thermo Fisher (NYSE: TMO)

Tycho Peterson

Jefferies

$650→$630

Buy

3.82%

Upside

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (NYSE: WST) and Thermo Fisher (NYSE: TMO)

Michael Ryskin

Bank of America Securities

$630→$650

Buy

7.12%

Upside

Reiterated

07/23/26

Thermo Fisher price target raised to $650 from $630 at BofAThermo Fisher price target raised to $650 from $630 at BofA

Eve Burstein

Bernstein

$520

Hold

-14.31%

Downside

Reiterated

07/22/26

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO) and Pfizer (NYSE: PFE)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

AXGNAxoGen

ATECAlphatec Holdings

CABACabaletta Bio

ONCBeOne Medicines

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Thermo Fisher

3 Months

Daniel AriasStifel Nicolaus

Success Rate

20/28 ratings generated profit

Average Return

+4.05%

Copying Daniel Arias's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +4.05% per trade.

1 Year

Patrick B DonnellyCiti

Success Rate

11/14 ratings generated profit

Average Return

+17.62%

Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +17.62% per trade.

2 Years

Michael RyskinBank of America Securities

Success Rate

19/21 ratings generated profit

Average Return

+18.31%

Copying Michael Ryskin's trades and holding each position for 2 Years would result in 90.48% of your transactions generating a profit, with an average return of +18.31% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0R0H Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0R0H has received 17 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 0R0H average Analyst price target in the past 3 months is 635.50.

Each month's total comprises the sum of three months' worth of ratings.

0R0H Financial Forecast

0R0H Earnings Forecast

Next quarter’s earnings estimate for 0R0H is $6.41 with a range of $6.33 to $6.56. The previous quarter’s EPS was $6.03. 0R0H beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0R0H has Performed in-line its overall industry.

0R0H Sales Forecast

Next quarter’s sales forecast for 0R0H is $11.95B with a range of $11.82B to $12.05B. The previous quarter’s sales results were $11.99B. 0R0H beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0R0H has Performed in-line its overall industry.

0R0H Stock Forecast FAQ

What is GB:0R0H’s average 12-month price target, according to analysts?

Based on analyst ratings, Thermo Fisher’s 12-month average price target is 635.50.

What is GB:0R0H’s upside potential, based on the analysts’ average price target?

Thermo Fisher has 4.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Thermo Fisher a Buy, Sell or Hold?

Thermo Fisher has a consensus rating of Strong Buy, which is based on 14 buy ratings, 3 hold ratings and 0 sell ratings.

What is Thermo Fisher’s share price target?

The average share price target for Thermo Fisher is 635.50. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $748.00 ,and the lowest forecast is $520.00. The average share price target represents 4.73% Increase from the current price of $606.81.

What do analysts say about Thermo Fisher?

Thermo Fisher’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of Thermo Fisher?

To buy shares of GB:0R0H, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Thermo Fisher (0R0H) Share Forecast & Price Target

0R0H Analyst Ratings

0R0H Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Thermo Fisher

0R0H Analyst Recommendation Trends

0R0H Financial Forecast

0R0H Earnings Forecast

0R0H Sales Forecast

0R0H Stock Forecast FAQ

Detailed List of Analyst Forecasts